Divis Laboratories reported results for the fourth quarter and year ended March 31, 2013.
The company has reported a fall of 15.34% in its net profit at Rs 181.83 crore in Q4FY13 as compared to net profit of Rs 214.78 crore in the same quarter previous year. Total income of the company has decreased by 7.95% to Rs 658.87 crore as compared to Rs 715.79 crore in corresponding quarter last year.
On consolidated basis, the company has reported a fall of 16.75% in its net profit at Rs 180.57 crore in Q4FY13 as compared to net profit of Rs 216.91 crore in the same quarter previous year. Total income of the company has decreased by 7.95% to Rs 665.10 crore as compared to Rs 722.53 crore in corresponding quarter last year.
For the year ended March 31, 2013, the company has registered 11.99% rise in its net profit at Rs 611.42 crore in FY13 as against Rs 545.97 crore in previous years. Total income of the company has increased to Rs 2177.40 crore as compared to Rs 1910.69 crore in FY12, up by 13.96%.
On consolidated basis, the group has registered 12.89% rise in its net profit at Rs 602.01 crore in FY13 as against Rs 533.26 crore in previous year. Total income of the company has increased to Rs 2189.65 crore as compared to Rs 1919.92 crore in FY12, up by 14.05%.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |